These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 33149632)
1. cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication. Dandri M; Petersen J Infect Drug Resist; 2020; 13():3873-3886. PubMed ID: 33149632 [TBL] [Abstract][Full Text] [Related]
2. Revisiting Hepatitis B Virus: Challenges of Curative Therapies. Hu J; Protzer U; Siddiqui A J Virol; 2019 Oct; 93(20):. PubMed ID: 31375584 [TBL] [Abstract][Full Text] [Related]
3. The Role of cccDNA in HBV Maintenance. Allweiss L; Dandri M Viruses; 2017 Jun; 9(6):. PubMed ID: 28635668 [TBL] [Abstract][Full Text] [Related]
4. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B]. Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795 [TBL] [Abstract][Full Text] [Related]
5. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844 [TBL] [Abstract][Full Text] [Related]
6. Hepatitis B Gene Therapy Coming to Age. Soriano V AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706 [TBL] [Abstract][Full Text] [Related]
7. Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. Lucifora J; Protzer U J Hepatol; 2016 Apr; 64(1 Suppl):S41-S48. PubMed ID: 27084036 [TBL] [Abstract][Full Text] [Related]
8. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA. Sheraz M; Cheng J; Tang L; Chang J; Guo JT J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306 [TBL] [Abstract][Full Text] [Related]
9. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504 [TBL] [Abstract][Full Text] [Related]
10. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Bohne F; Chmielewski M; Ebert G; Wiegmann K; Kürschner T; Schulze A; Urban S; Krönke M; Abken H; Protzer U Gastroenterology; 2008 Jan; 134(1):239-47. PubMed ID: 18166356 [TBL] [Abstract][Full Text] [Related]
11. Can we cure hepatitis B virus with novel direct-acting antivirals? Martinez MG; Villeret F; Testoni B; Zoulim F Liver Int; 2020 Feb; 40 Suppl 1():27-34. PubMed ID: 32077597 [TBL] [Abstract][Full Text] [Related]
12. Aiming for cure in HBV and HDV infection. Petersen J; Thompson AJ; Levrero M J Hepatol; 2016 Oct; 65(4):835-848. PubMed ID: 27270043 [TBL] [Abstract][Full Text] [Related]
13. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Yang HC; Kao JH Emerg Microbes Infect; 2014 Sep; 3(9):e64. PubMed ID: 26038757 [TBL] [Abstract][Full Text] [Related]
14. Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus. Kim SW; Yoon JS; Lee M; Cho Y Clin Mol Hepatol; 2022 Jan; 28(1):17-30. PubMed ID: 34281294 [TBL] [Abstract][Full Text] [Related]
15. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Allweiss L; Volz T; Giersch K; Kah J; Raffa G; Petersen J; Lohse AW; Beninati C; Pollicino T; Urban S; Lütgehetmann M; Dandri M Gut; 2018 Mar; 67(3):542-552. PubMed ID: 28428345 [TBL] [Abstract][Full Text] [Related]
16. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Zhang W; Chen J; Wu M; Zhang X; Zhang M; Yue L; Li Y; Liu J; Li B; Shen F; Wang Y; Bai L; Protzer U; Levrero M; Yuan Z Hepatology; 2017 Aug; 66(2):398-415. PubMed ID: 28236308 [TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901 [TBL] [Abstract][Full Text] [Related]
18. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799 [TBL] [Abstract][Full Text] [Related]
19. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704 [TBL] [Abstract][Full Text] [Related]
20. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. Boyd A; Lacombe K; Lavocat F; Maylin S; Miailhes P; Lascoux-Combe C; Delaugerre C; Girard PM; Zoulim F J Hepatol; 2016 Oct; 65(4):683-691. PubMed ID: 27210429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]